Found: 151
Select item for more details and to access through your institution.
Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Mechanisms of skin aging induced by EGFR inhibitors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Xerosis and pruritus as major EGFRI-associated adverse events.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 6, p. 1247, doi. 10.1007/s10637-019-00825-0
- By:
- Publication type:
- Article
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 6, p. 742, doi. 10.1007/s10637-017-0445-0
- By:
- Publication type:
- Article
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 1078, doi. 10.1007/s10637-013-9977-0
- By:
- Publication type:
- Article
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 787, doi. 10.1007/s10637-013-9927-x
- By:
- Publication type:
- Article
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1773, doi. 10.1007/s10637-011-9652-2
- By:
- Publication type:
- Article
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1114, doi. 10.1007/s10637-010-9567-3
- By:
- Publication type:
- Article
Blackberry-induced hand-foot skin reaction to sunitinib.
- Published in:
- 2009
- By:
- Publication type:
- Correction notice
Blackberry-induced hand-foot skin reaction to sunitinib.
- Published in:
- 2009
- By:
- Publication type:
- Report
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 10, p. 2933, doi. 10.1007/s00520-013-1896-2
- By:
- Publication type:
- Article
Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events.
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 7, p. 1919, doi. 10.1007/s00520-013-1752-4
- By:
- Publication type:
- Article
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 4, p. 1033, doi. 10.1007/s00520-012-1623-4
- By:
- Publication type:
- Article
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 4, p. 1167, doi. 10.1007/s00520-012-1645-y
- By:
- Publication type:
- Article
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Skin care management in cancer patients: an evaluation of quality of life and tolerability.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Unanticipated toxicities from anticancer therapies: survivors' perspectives.
- Published in:
- 2010
- By:
- Publication type:
- journal article
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
- Published in:
- Supportive Care in Cancer, 2010, v. 18, n. 4, p. 509, doi. 10.1007/s00520-009-0744-x
- By:
- Publication type:
- Article
Skin necrosis induced by generic enoxaparin.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 4, p. 339, doi. 10.1002/ajh.23401
- By:
- Publication type:
- Article
Photodermatosis associated with eculizumab (Soliris): A novel monoclonal antibody directed against the complement protein C5.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 5, p. 392, doi. 10.1002/ajh.21672
- By:
- Publication type:
- Article
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.
- Published in:
- Journal of Patient-Reported Outcomes, 2020, v. 4, n. 1, p. 1, doi. 10.1186/s41687-020-00220-x
- By:
- Publication type:
- Article
Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors <sub>Awareness, Education, and Literature Review</sub>.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Dermatologic Challenges in Cancer Patients and Survivors.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 12, p. 1462
- By:
- Publication type:
- Article
Dermatologic Toxicities Associated With EGFR Inhibitors: The Clinical Psychologist's Perspective.
- Published in:
- Oncology (08909091), 2007, v. 21, p. 34
- By:
- Publication type:
- Article
Clinical Management of EGFRI Dermatologic Toxicities: US Perspective.
- Published in:
- Oncology (08909091), 2007, v. 21, p. 17
- By:
- Publication type:
- Article
Clinical Presentation and Pathophysiology of EGFRI Dermatologic Toxicities.
- Published in:
- Oncology (08909091), 2007, v. 21, p. 4
- By:
- Publication type:
- Article
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.01045
- By:
- Publication type:
- Article
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report.
- Published in:
- Case Reports in Oncology, 2021, v. 14, n. 1, p. 430, doi. 10.1159/000514345
- By:
- Publication type:
- Article
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
- Published in:
- PLoS ONE, 2022, v. 17, n. 1, p. 1, doi. 10.1371/journal.pone.0262151
- By:
- Publication type:
- Article
EMPACT syndrome: limited evidence despite a high-risk cohort.
- Published in:
- Journal of Neuro-Oncology, 2014, v. 119, n. 1, p. 129, doi. 10.1007/s11060-014-1457-7
- By:
- Publication type:
- Article
Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 1, p. 47, doi. 10.1093/jnci/djp439
- By:
- Publication type:
- Article
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
- Published in:
- Annals of Clinical & Translational Neurology, 2020, v. 7, n. 4, p. 429, doi. 10.1002/acn3.51009
- By:
- Publication type:
- Article
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 29, doi. 10.1007/s13555-021-00624-7
- By:
- Publication type:
- Article
Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.
- Published in:
- 2020
- By:
- Publication type:
- case study
Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 4, p. 424, doi. 10.1016/j.clml.2013.03.006
- By:
- Publication type:
- Article
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 1, p. 53, doi. 10.1038/s41416-023-02487-5
- By:
- Publication type:
- Article
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 2, p. 271, doi. 10.1007/s10549-023-07143-3
- By:
- Publication type:
- Article
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 194, n. 1, p. 57, doi. 10.1007/s10549-022-06584-6
- By:
- Publication type:
- Article
A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 186, n. 1, p. 107, doi. 10.1007/s10549-020-06005-6
- By:
- Publication type:
- Article
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 183, n. 1, p. 227, doi. 10.1007/s10549-020-05726-y
- By:
- Publication type:
- Article
The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 175, n. 2, p. 267, doi. 10.1007/s10549-019-05169-0
- By:
- Publication type:
- Article
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 174, n. 1, p. 15, doi. 10.1007/s10549-018-4996-3
- By:
- Publication type:
- Article
Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia.
- Published in:
- 2016
- By:
- Publication type:
- Report
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 147, n. 3, p. 631, doi. 10.1007/s10549-014-3126-0
- By:
- Publication type:
- Article
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
- Published in:
- 2014
- By:
- Publication type:
- Report